160 related articles for article (PubMed ID: 11985564)
1. Expression of CD40, CD44, bcl-2 antigens and rate of cell proliferation on fine needle aspirates from metastatic melanoma.
Sviatoha V; Rundgren A; Tani E; Hansson J; Kleina R; Skoog L
Cytopathology; 2002 Feb; 13(1):11-21. PubMed ID: 11985564
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemically detectable bcl-2 expression in metastatic melanoma: association with survival and treatment response.
Vlaykova T; Talve L; Hahka-Kemppinen M; Hernberg M; Muhonen T; Collan Y; Pyrhönen S
Oncology; 2002; 62(3):259-68. PubMed ID: 12065874
[TBL] [Abstract][Full Text] [Related]
3. Bcl-2 expression is not associated with survival in metastatic cutaneous melanoma: a historical cohort study.
Espíndola MB; Corleta OC
World J Surg Oncol; 2008 Jun; 6():65. PubMed ID: 18570663
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of biomarkers in malignant melanoma.
Hernberg M; Turunen JP; von Boguslawsky K; Muhonen T; Pyrhönen S
Melanoma Res; 1998 Jun; 8(3):283-91. PubMed ID: 9664152
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of the S100A1, S100B, CD44 and Bcl-2 antigens and the rate of cell proliferation assessed by Ki-67 antibody in benign and malignant melanocytic tumours.
Sviatoha V; Tani E; Kleina R; Sperga M; Skoog L
Melanoma Res; 2010 Apr; 20(2):118-25. PubMed ID: 20042890
[TBL] [Abstract][Full Text] [Related]
6. Integrin chains beta1 and alphav as prognostic factors in human metastatic melanoma.
Nikkola J; Vihinen P; Vlaykova T; Hahka-Kemppinen M; Heino J; Pyrhönen S
Melanoma Res; 2004 Feb; 14(1):29-37. PubMed ID: 15091191
[TBL] [Abstract][Full Text] [Related]
7. Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients.
Gradilone A; Gazzaniga P; Ribuffo D; Scarpa S; Cigna E; Vasaturo F; Bottoni U; Innocenzi D; Calvieri S; Scuderi N; Frati L; Aglianò AM
J Clin Oncol; 2003 Jan; 21(2):306-12. PubMed ID: 12525523
[TBL] [Abstract][Full Text] [Related]
8. Reduced level of CD44 and hyaluronan associated with unfavorable prognosis in clinical stage I cutaneous melanoma.
Karjalainen JM; Tammi RH; Tammi MI; Eskelinen MJ; Agren UM; Parkkinen JJ; Alhava EM; Kosma VM
Am J Pathol; 2000 Sep; 157(3):957-65. PubMed ID: 10980134
[TBL] [Abstract][Full Text] [Related]
9. CD44 and variants in melanocytic skin neoplasms.
Schaider H; Soyer HP; Heider KH; Hofmann-Wellenhof R; Zatloukal K; Smolle J; Kerl H
J Cutan Pathol; 1998 Apr; 25(4):199-203. PubMed ID: 9609138
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis of Bcl-2, nuclear S100A4, MITF and Ki67 for risk stratification of early-stage melanoma - A combined IHC score for melanoma risk stratification.
Jurmeister P; Bockmayr M; Treese C; Stein U; Lenze D; Jöhrens K; Friedling F; Dietel M; Klauschen F; Marsch W; Fiedler E; von Laffert M
J Dtsch Dermatol Ges; 2019 Aug; 17(8):800-808. PubMed ID: 31437373
[TBL] [Abstract][Full Text] [Related]
11. Increased Angiogenesis and Lymphangiogenesis in Metastatic Sentinel Lymph Nodes Is Associated With Nonsentinel Lymph Node Involvement and Distant Metastasis in Patients With Melanoma.
Pastushenko I; Van den Eynden GG; Vicente-Arregui S; Prieto-Torres L; Alvarez-Alegret R; Querol I; Dirix LY; Carapeto FJ; Vermeulen PB; Van Laere SJ
Am J Dermatopathol; 2016 May; 38(5):338-46. PubMed ID: 26909582
[TBL] [Abstract][Full Text] [Related]
12. Moesin and CD44 expression in cutaneous melanocytic tumours.
Ichikawa T; Masumoto J; Kaneko M; Saida T; Sagara J; Taniguchi S
Br J Dermatol; 1998 May; 138(5):763-8. PubMed ID: 9666819
[TBL] [Abstract][Full Text] [Related]
13. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma.
Zhuang L; Lee CS; Scolyer RA; McCarthy SW; Zhang XD; Thompson JF; Hersey P
Mod Pathol; 2007 Apr; 20(4):416-26. PubMed ID: 17384650
[TBL] [Abstract][Full Text] [Related]
14. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors.
Monteagudo C; Martin JM; Jorda E; Llombart-Bosch A
J Clin Pathol; 2007 Jun; 60(6):596-9. PubMed ID: 16522748
[TBL] [Abstract][Full Text] [Related]
15. Ki-67, Bcl-2 and p53 expression in primary and metastatic melanoma.
Ilmonen S; Hernberg M; Pyrhönen S; Tarkkanen J; Asko-Seljavaara S
Melanoma Res; 2005 Oct; 15(5):375-81. PubMed ID: 16179864
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of apoptosis and associated factors in oral squamous cell carcinoma.
Stoll C; Baretton G; Ahrens C; Löhrs U
Virchows Arch; 2000 Feb; 436(2):102-8. PubMed ID: 10755598
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of beta1 integrin expression in metastatic melanoma.
Vihinen P; Nikkola J; Vlaykova T; Hahka-Kemppinen M; Talve L; Heino J; Pyrhönen S
Melanoma Res; 2000 Jun; 10(3):243-51. PubMed ID: 10890378
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis.
Bhatavdekar JM; Patel DD; Shah NG; Vora HH; Suthar TP; Chikhlikar PR; Ghosh N; Trivedi TI
Ann Surg Oncol; 2000 May; 7(4):305-11. PubMed ID: 10819372
[TBL] [Abstract][Full Text] [Related]
19. Detection of melanoma cells in sentinel lymph nodes, bone marrow and peripheral blood by a reverse transcription-polymerase chain reaction assay in patients with primary cutaneous melanoma: association with Breslow's tumour thickness.
Blaheta HJ; Paul T; Sotlar K; Maczey E; Schittek B; Paul A; Moehrle M; Breuninger H; Bueltmann B; Rassner G; Garbe C
Br J Dermatol; 2001 Aug; 145(2):195-202. PubMed ID: 11531779
[TBL] [Abstract][Full Text] [Related]
20. Merkel cell carcinoma: mitoses, expression of Ki-67 and bcl-2 correlate with disease progression.
Vujic I; Marker M; Posch C; Mühlehner D; Monshi B; Breier F; Steiner A; Ortiz-Urda S; Rappersberger K
J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):542-8. PubMed ID: 25088273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
